Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.
Τίτλος | Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Makras, P., Polyzos S. A., Papatheodorou A., Kokkoris P., Chatzifotiadis D., & Anastasilakis A. D. |
Journal | Clin Endocrinol (Oxf) |
Volume | 79 |
Issue | 4 |
Pagination | 499-503 |
Date Published | 2013 Oct |
ISSN | 1365-2265 |
Λέξεις κλειδιά | Aged, Antibodies, Monoclonal, Humanized, Bone Density, Calcium, Calcium Carbonate, Cholecalciferol, Denosumab, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Middle Aged, Osteoporosis, Postmenopausal, Parathyroid Hormone, Prospective Studies, Time Factors, Treatment Outcome, Vitamins |
Abstract | OBJECTIVE: Denosumab is a new potent antiresorptive treatment of osteoporosis that can potentially induce a compensatory increase in parathyroid hormone (PTH) levels. We aimed to evaluate the alteration of PTH 1 and 6 months after denosumab's administration with different regimens of calcium and vitamin D (Ca/D) supplementation. |
DOI | 10.1111/cen.12188 |
Alternate Journal | Clin. Endocrinol. (Oxf) |
PubMed ID | 23452098 |